

SMALL CELL LUNG CANCER: Patients report

M.P. Molina Guillén¹, J. Pastor Cano¹, J. León Villar¹, M.C. Sánchez Mulero¹, B. Arribas Díaz¹, A. Bosó Ribelles¹, A. Moregó Soler¹, M.I Sánchez-Quiles¹, J.F. Abellán².

¹ Hospital Morales Meseguer, Hospital pharmacy, Murcia, Spain.

² Hospital Morales Meseguer, Surgery, Murcia, Spain.

Purpose

The aim of this study is to evaluate the progression-free interval (PFI) on SCLC patients receiving first line platinum based chemotherapy.


Materials and Methods

- Retrospective observational study focused on patients diagnosed during two years (2009-2010).
- Data were collected from medical records (treatment orders, Oncofarm® program and medical history).
- These data were: age, sex, history of smoking, stage of the disease, treatments received, and PFI.


Results

- Forty patients were diagnosed with SCLC. 4 (10%) were women and 36 (90%) were men.
- Fifteen (37.5%) were diagnosed at the limited stage disease (LD) and 25 (62.5%) at extended stage disease (ED).
- Average first line platinum chemotherapy cycles received were 3 (1-6), and two patients did not receive any treatment (1 of LD group, 1 of ED group).

➤ First line treatment results on LD patients:



➤ First line treatment results on ED patients:



Conclusions

- * Platinum based chemotherapy has been shown to be more effective in SCLC patients when they start the treatment at the LD stage.
- * The 73.3% of the patients diagnosed and treated at the LD stage had a PFI longer than 6 months.
- * Only 28% of the patients who started the treatment at the ED stage reached a PFI longer than 6 months.